EyePoint Is Betting The Bank On EYP-1901 [Seeking Alpha]
Alimera Sciences, Inc. (ALIM)
Last alimera sciences, inc. earnings: 4/29 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.alimerasciences.com/investor-relations
Company Research
Source: Seeking Alpha
The company has a strong drug delivery platform with Durasert and has sold off its profitable YUTIQ business. EYP-1901 targets multi-billion dollar markets in wet AMD, NPDR, and DME, but it's not entirely a slam dunk as competition is increasing. Looking for more investing ideas like this one? Get them exclusively at SHU Growth Portfolio. Learn More » EyePoint ( NASDAQ: EYPT ) has a potential blockbuster with EYP-1901 after a successful P2 trial that met all its endpoints in a very promising development. It sold off its remaining drug YUTIQ and reverted to a pure development company, betting the bank on EYP-1901. EYP-1901 has three possible uses (Wet AMD, NPDR and DME) each of which are multi-billion dollar markets, but after rising 400%+ in less than a year, the stock isn't a home run anymore and risks remain. A quick recap, the company developed Durasert , a slow-delivery intravitreal drug platform that has been approved for four drugs. The company has multiple things g
Show less
Read more
Impact Snapshot
Event Time:
ALIM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALIM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALIM alerts
High impacting Alimera Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
ALIM
News
- Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update [Yahoo! Finance]Yahoo! Finance
- Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate UpdateGlobeNewswire
- Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Alimera Sciences, Inc. (NASDAQ: ALIM) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Alimera Sciences, Inc. (NASDAQ: ALIM) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
ALIM
Earnings
- 3/7/24 - Miss
ALIM
Sec Filings
- 4/29/24 - Form 10-K/A
- 4/2/24 - Form 4
- 3/13/24 - Form 4
- ALIM's page on the SEC website